FDA grants priority review for ZOMETA.
D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D002986:Clinical Trials as Topic; D004164:Diphosphonates / Q000009:adverse effects / Q000627:therapeutic use*; D017277:Drug Approval; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration; D000077211:Zoledronic Acid
D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid